CEACAM6 is associated with osteosarcoma metastasis and facilitates epithelial–mesenchymal transition in osteosarcoma cells
Authors Wang Z, Luo C, Wang H, Yan X, Liu W, Meng Z
Received 7 January 2018
Accepted for publication 8 April 2018
Published 28 May 2018 Volume 2018:11 Pages 3159—3166
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Cristina Weinberg
Peer reviewer comments 3
Editor who approved publication: Dr Samir Farghaly
Zeyu Wang,1 Chong Luo,1 Huidan Wang,2 Xia Yan,2 Wei Liu,1 Zengdong Meng1
1Department of Orthopaedics, The First People’s Hospital of Yunnan Province, Dali 650000, Yunnan, People’s Republic of China; 2Medical Faculty, Kunming University of Science and Technology, Dali 650000, Yunnan, People’s Republic of China
Background: Carcinoembryonic antigen-related cell adhesion molecule 6 (CEACAM6) is a member of CEACAM family and has been reported to be upregulated in various types of human cancer and involved in tumor progression and metastasis. However, the biological roles and clinical significances of CEACAM6 in osteosarcoma still remain to be elucidated.
Materials and methods: Real-time PCR, immunohistochemistry and Western blot analysis were used to determine CEACAM6 expression in osteosarcoma cell lines and clinical specimens. Then the clinical relevance of CEACAM6 was analyzed in osteosarcoma. The function of CEACAM6 in osteosarcoma was examined by wound-healing and cell invasion assays, and expression levels of epithelial–mesenchymal transition markers.
Results: In the present study, we found that CEACAM6 was markedly upregulated in metastatic osteosarcoma tissues when compared with the nonmetastatic osteosarcoma tissues. Upregulation of CEACAM6 was significantly associated with lung metastasis status (P=0.006) in patients with osteosarcoma. Survival analyses suggested that osteosarcoma patients with high CEACAM6 expression had a significantly shorter overall survival time and lung metastasis-free survival time than those with low CEACAM6 expression. Knockdown of CEACAM6 inhibits osteosarcoma cell migration and invasion. Moreover, silencing CEACAM6 suppressed osteosarcoma cells epithelial–mesenchymal transition.
Conclusion: Taken together, this study suggests that CEACAM6 might be a promising biomarker and a potential therapeutic target for the treatment of metastatic osteosarcoma.
Keywords: CEACAM6, osteosarcoma, metastasis, epithelial–mesenchymal transition, prognosis
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]